- Home
- DUO vs ADXN Comparison
DUO vs ADXN Comparison
Compare DUO & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DUO | ADXN |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.0M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DUO | ADXN |
|---|---|---|
| Price | $1.38 | $7.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.8K | 5.2K |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $5.41 |
| 52 Week High | $5.34 | $12.05 |
Technical Indicators
Market Signals| Indicator | DUO | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 67.53 | 54.40 |
| Support Level | $1.25 | $5.49 |
| Resistance Level | $1.78 | $7.38 |
| Average True Range (ATR) | 0.09 | 0.55 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 76.51 | 73.97 |
Price Performance
Historical ComparisonAbout DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.